David M Jackman MD

Hematologic Oncology, Thoracic Cancer

Medical Director of Clinical Pathways, Dana-Farber Cancer Institute; Senior Physician, DFCI; Assistant Professor of Medicine, Harvard Medical School

Join to view full profile

Dana-Farber Cancer Institute450 Brookline AveBoston, MA 02215
Phone+1 617-632-3468
Fax+1 617-632-5786

Dr. Jackman is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jackman's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2000 - 2003
The Warren Alpert Medical School of Brown UniversityClass of 2000

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2023 - Present
ME State Medical License 2025 - 2028
NH State Medical License 2009 - 2028
RI State Medical License 2023 - 2028
CT State Medical License 2023 - 2027
MA State Medical License 2004 - 2027
OH State Medical License 2023 - 2027
VT State Medical License 2023 - 2026
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017

Clinical Trials

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
COMPLETED
PHASE2
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants Start of enrollment: 2013 Dec 12
TERMINATED
PHASE2
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
COMPLETED
PHASE2

Publications & Presentations

PubMed

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC): A Randomized Clinical Trial.
Christopher R Manz, Cody E Cotner, Angela C Tramontano, Saima Awan, Nathaniel Gwynne
Journal of the National Comprehensive Cancer Network. 2026-06-01
4 citations
Using Oncology Treatment Pathway Data to Evaluate Serious Illness Communication, Care Utilization, and End-of-Life Care for Patients With Cancer.
Cody E Cotner, Angela C Tramontano, Alex Post, Brian Finn, Saima Awan
JCO Oncology Practice. 2025-04-01
4 citations
Phase II Study of Defactinib (VS6063) in Patients With Tumors WithLoss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, James A Zwiebel, Robert J Gray
JCO Precision Oncology. 2024-12-01

Press Mentions

Cancer Without Chemotherapy: ‘A Totally Different World’September 27th, 2021
What Mesothelioma Awareness Day Means to a SurvivorSeptember 26th, 2019
Royal Philips : Philips IntelliSpace Precision Medicine Oncology Pathways Powered by Dana-Farber Is Now LiveSeptember 11th, 2019